Q4 2019 Richter Gedeon Vegyeszeti Gyar Nyrt Earnings Call Transcript
Mr. Gabor Orban, CEO. Please go ahead, sir.
Thank you very much. Good morning, everyone. Thank you for joining this call this morning. I'd like to begin by saying that I am very pleased with the significant progress that we achieved last year in shifting the composition of our sales turnover towards specialty products and key specialty projects. And we are now at 50%-plus share of the specialty-related turnover out of total pharma sales, which I think is a good step in the right direction and an important step in executing our strategy.
Last year consolidated sales moved higher at the double digit rate, and also the pharma segment saw the top-line move up by more than 10%, 11.7.
The strong increase in wholesale and retail is not an imminent part of the business strategy. It has to do with primarily with the basis that given that our [houses] were closed down in 2018. So we have this technical effect pushing the figures higher. That said, the pharma sales went up as a consequence of business related core
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
